Regenxbio Reports the Initiation of First Pivotal Program for RGX-314 to Treat Wet AMD
Shots:
- Regenxbio has reported that the ATMOSPHERE trial evaluating RGX-314 is active and patient screening is ongoing. The study will enroll 300 patients across two RGX-314 dose arms vs ranibizumab- with anticipated initiation of patients dosing in Q1’21
- The second trial is expected to be similar in design to ATMOSPHERE with its expected initiation in H1’21. The company expects to submit a BLA based on these trials in 2024
- The company has completed enrollment of patients in Cohort 1 of the P-II AAVIATE study for wet AMD. Moreover- Regenxbio reported a new program RGX-202 for DMD with its expected IND filing in mid-2021
Ref: PRNewswire | Image: BioHealth Capital Region
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com